Sage Therapeutics, Inc.
SAGE
$6.75
$0.192.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 13.83M | 12.82M | 11.87M | 8.65M | 7.90M |
| Total Other Revenue | 236.00K | -- | -- | -- | -- |
| Total Revenue | 14.06M | 12.82M | 11.87M | 8.65M | 7.90M |
| Cost of Revenue | 23.41M | 55.08M | 54.37M | 63.97M | 73.00M |
| Gross Profit | -9.35M | -42.26M | -42.50M | -55.32M | -65.10M |
| SG&A Expenses | 57.59M | 54.65M | 53.22M | 55.98M | 52.57M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 81.01M | 93.16M | 113.07M | 119.95M | 125.58M |
| Operating Income | -66.94M | -80.34M | -101.20M | -111.30M | -117.68M |
| Income Before Tax | -62.21M | -95.78M | -93.55M | -102.85M | -108.48M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -62.21M | -95.78M | -93.55M | -102.85M | -108.48M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -62.21M | -95.78M | -93.55M | -102.85M | -108.48M |
| EBIT | -66.94M | -80.34M | -101.20M | -111.30M | -117.68M |
| EBITDA | -66.83M | -80.21M | -100.95M | -110.99M | -117.34M |
| EPS Basic | -1.01 | -1.56 | -1.53 | -1.70 | -1.80 |
| Normalized Basic EPS | -0.62 | -0.75 | -0.96 | -1.06 | -1.13 |
| EPS Diluted | -1.01 | -1.56 | -1.53 | -1.70 | -1.80 |
| Normalized Diluted EPS | -0.62 | -0.75 | -0.96 | -1.06 | -1.13 |
| Average Basic Shares Outstanding | 61.86M | 61.26M | 61.12M | 60.54M | 60.14M |
| Average Diluted Shares Outstanding | 61.86M | 61.26M | 61.12M | 60.54M | 60.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |